Janssen Daphne J, Carnielli Virgilio P, Cogo Paola, Bohlin Kajsa, Hamvas Aaron, Luijendijk Ingrid H, Bunt Jan Erik H, Tibboel Dick, Zimmermann Luc J
Erasmus MC-Sophia, Division of Neonatology and Pediatric Surgery, Rotterdam, The Netherlands.
J Pediatr. 2006 Nov;149(5):634-9. doi: 10.1016/j.jpeds.2006.07.027.
Because meconium directly inhibits surfactant function, we sought to determine the effect of meconium on endogenous surfactant synthesis and clearance.
We studied surfactant phosphatidylcholine kinetics with the use of stable isotopes in 11 newborn infants with meconium aspiration syndrome (MAS) who required extracorporeal membrane oxygenation (ECMO). For comparison we studied 6 neonates with persistent pulmonary hypertension (PPHN) on ECMO and 10 term neonates ventilated for non-pulmonary indications and not on ECMO. All patients received a 24-hour [U- 13C]glucose infusion as precursor for the palmitic acid in surfactant phosphatidylcholine.
In the meconium group, the maximal 13C-incorporation in phosphatidylcholine (PC) was half of that in controls (0.09 +/- 0.01 vs 0.18 +/- 0.03 atom percent excess [APE], P = .027). There was a trend toward lower surfactant synthesis in the MAS group (3.3 +/- 0.7%/day) and PPHN group (2.6 +/- 0.3%/day) compared with controls 8.0 +/- 2.4%/day, P = .058). Significantly lower PC concentrations in tracheal aspirates were found in the MAS group (4.4 +/- 2.6 mg/mL) and PPHN group (3.6 +/- 2.0 mg/mL) compared with controls (12.8 +/- 2.6 mg/mL, P = .01). Endogenously synthesized surfactant had a similar half-life in all groups, ranging from 63 to 98 hours.
We conclude that surfactant synthesis is disturbed and that surfactant PC concentrations are low in infants with MAS on ECMO.
由于胎粪可直接抑制表面活性物质的功能,我们试图确定胎粪对内源性表面活性物质合成及清除的影响。
我们使用稳定同位素研究了11例需要体外膜肺氧合(ECMO)的胎粪吸入综合征(MAS)新生儿的表面活性物质磷脂酰胆碱动力学。作为对照,我们研究了6例接受ECMO治疗的持续性肺动脉高压(PPHN)新生儿以及10例因非肺部指征接受机械通气且未使用ECMO的足月儿。所有患者均接受24小时的[U-13C]葡萄糖输注,作为表面活性物质磷脂酰胆碱中棕榈酸的前体。
在胎粪组中,磷脂酰胆碱(PC)的最大13C掺入量仅为对照组的一半(0.09±0.01对0.18±0.03原子百分超量[APE],P = 0.027)。与对照组(8.0±2.4%/天)相比,MAS组(3.3±0.7%/天)和PPHN组(2.6±0.3%/天)的表面活性物质合成有降低趋势(P = 0.058)。与对照组(12.8±2.6mg/mL)相比,MAS组(4.4±2.6mg/mL)和PPHN组气管吸出物中的PC浓度显著降低(P = 0.01)。内源性合成的表面活性物质在所有组中的半衰期相似,为63至98小时。
我们得出结论,接受ECMO治疗的MAS婴儿的表面活性物质合成受到干扰,且表面活性物质PC浓度较低。